Evista (raloxifene)
- Region
- 🇪🇺 EU
- Active substance
- raloxifene
- Company
- Substipharm
- Status
- Authorised
- Therapeutic area
- Osteoporosis, Postmenopausal
- CHMP opinion
- Wed 22 Apr 1998
- EU approval
- Wed 05 Aug 1998
- Application
- EMEA/H/C/000184
- ATC
- G03XC01
- Official record
- www.ema.europa.eu
Indication
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Optruma Withdrawn · Eli Lilly Nederland B.V.
- 🇪🇺 Raloxifene Teva Authorised · Teva B.V.
Follow Evista
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.